These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 32464123)

  • 1. The role of metabolic diseases in cardiotoxicity associated with cancer therapy: What we know, what we would know.
    L'Abbate S; Russo I; Kusmic C
    Life Sci; 2020 Aug; 255():117843. PubMed ID: 32464123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies to Prevent Cardiotoxicity.
    Graffagnino J; Kondapalli L; Arora G; Hawi R; Lenneman CG
    Curr Treat Options Oncol; 2020 Apr; 21(4):32. PubMed ID: 32270293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy-induced cardiotoxicity: new insights into mechanisms, monitoring, and prevention.
    Cadeddu Dessalvi C; Deidda M; Mele D; Bassareo PP; Esposito R; Santoro C; Lembo M; Galderisi M; Mercuro G
    J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):315-323. PubMed ID: 29708912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy-induced cardiotoxicity in children.
    Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular safety of oncologic agents: A double-edged sword even in the era of targeted therapies - part 1.
    Manolis AA; Manolis TA; Mikhailidis DP; Manolis AS
    Expert Opin Drug Saf; 2018 Sep; 17(9):875-892. PubMed ID: 30126304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.
    Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM
    CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardio-oncology: the new frontier of clinical and preventive cardiology.
    Paris S; Tarantini L; Navazio A; Faggiano P
    Monaldi Arch Chest Dis; 2020 Jun; 90(2):. PubMed ID: 32571000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular safety of oncologic agents: a double-edged sword even in the era of targeted therapies - Part 2.
    Manolis AA; Manolis TA; Mikhailidis DP; Manolis AS
    Expert Opin Drug Saf; 2018 Sep; 17(9):893-915. PubMed ID: 30126303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of the Metabolism of Anticancer Drugs in Their Induced-Cardiotoxicity.
    Reis-Mendes AF; Sousa E; de Lourdes Bastos M; Costa VM
    Curr Drug Metab; 2015; 17(1):75-90. PubMed ID: 26526839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological foundations of cardio-oncology.
    Minotti G; Salvatorelli E; Menna P
    J Pharmacol Exp Ther; 2010 Jul; 334(1):2-8. PubMed ID: 20335321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiotoxicity: anthracyclines and long term cancer survivors.
    Patanè S
    Int J Cardiol; 2014 Oct; 176(3):1326-8. PubMed ID: 25129289
    [No Abstract]   [Full Text] [Related]  

  • 12. Protective Effects of ω-3 PUFA in Anthracycline-Induced Cardiotoxicity: A Critical Review.
    Serini S; Ottes Vasconcelos R; Nascimento Gomes R; Calviello G
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29231904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardio-oncology Part I: chemotherapy and cardiovascular toxicity.
    O'Hare M; Sharma A; Murphy K; Mookadam F; Lee H
    Expert Rev Cardiovasc Ther; 2015 May; 13(5):511-8. PubMed ID: 25843285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy-induced cardiomyopathy.
    Higgins AY; O'Halloran TD; Chang JD
    Heart Fail Rev; 2015 Nov; 20(6):721-30. PubMed ID: 26338137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cardiotoxicity of anticancer therapies. Towards the implementation of cardio-oncology units].
    Hameau R; Gabrielli L; Garrido M; Guzmán AM; Retamal I; Vacarezza MJ; Greig D; Ocqueteau M; Sánchez C; Pizarro M; Corvalán A; Lavandero S; Castro PF; Martínez G
    Rev Med Chil; 2018 Jan; 146(1):68-77. PubMed ID: 29806680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular Toxicity in Cancer Therapy: Protecting the Heart while Combating Cancer.
    Manhas A; Tripathi D; Thomas D; Sayed N
    Curr Cardiol Rep; 2024 Sep; 26(9):953-971. PubMed ID: 39042344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current views on anthracycline cardiotoxicity.
    Mele D; Nardozza M; Spallarossa P; Frassoldati A; Tocchetti CG; Cadeddu C; Madonna R; Malagù M; Ferrari R; Mercuro G
    Heart Fail Rev; 2016 Sep; 21(5):621-34. PubMed ID: 27230651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.
    Spallarossa P; Maurea N; Cadeddu C; Madonna R; Mele D; Monte I; Novo G; Pagliaro P; Pepe A; Tocchetti CG; Zito C; Mercuro G
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1(Suppl 1):e84-e92. PubMed ID: 27183529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiotoxicity of Targeted Cancer Drugs: Concerns, "The Cart Before the Horse," and Lessons from Trastuzumab.
    Menna P; Minotti G; Salvatorelli E
    Curr Cardiol Rep; 2019 Mar; 21(5):33. PubMed ID: 30887161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Comprehensive Review of Cancer Drug-Induced Cardiotoxicity in Blood Cancer Patients: Current Perspectives and Therapeutic Strategies.
    Costanzo V; Ratre YK; Andretta E; Acharya R; Bhaskar LVKS; Verma HK
    Curr Treat Options Oncol; 2024 Apr; 25(4):465-495. PubMed ID: 38372853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.